NMS · Financial Statements

Immunovant, Inc. (IMVT) Financial Statements

$28.25 NMS: IMVT Market Cap $5.84B

Immunovant, Inc. most recently reported annual revenue of $0, a net loss of $506.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Immunovant, Inc.: net profit was positive in 0 of 9 reported years; the most recent year shows a net loss of $506.0M.

Income Statement — 9 Years (USD millions)

Metric201820192020202120222023202420252026
Revenue$0$0$0$0$0$0$0$0$0
Operating Expenses$137.0M$0$60.0M$108.0M$156.0M$208.0M$270.0M$438.0M$533.0M
Operating Profit$-137.0M$0$-60.0M$-108.0M$-156.0M$-208.0M$-270.0M$-438.0M$-533.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other Income$0$0$-7.0M$0$-1.0M$-3.0M$11.0M$25.0M$28.0M
Interest$0$0$1.0M$0$0$12.0M$0$0$0
Depreciation$137.0M$0$0$0$0$0$0$0$0
Profit Before Tax$-137.0M$0$-66.0M$-108.0M$-157.0M$-211.0M$-259.0M$-413.0M$-505.0M
Tax$0$0$-150,000$330,000$50,000$0$-220,000$-220,000$-40,000
Net Profit$-137.0M$0$-66.0M$-107.0M$-157.0M$-211.0M$-259.0M$-414.0M$-506.0M
EPS$-13.67$0.00$-1.54$-1.22$-1.43$-1.71$-1.88$-2.73$-2.77
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$7.0M
Operating Expenses$62.0M$62.0M$81.0M$94.0M$116.0M$114.0M$114.0M$127.0M$132.0M$114.0M$160.0M$160.0M
Operating Profit$-62.0M$-62.0M$-81.0M$-94.0M$-116.0M$-114.0M$-114.0M$-127.0M$-132.0M$-114.0M$-160.0M$-153.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%-2159.7%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-58.0M$-52.0M$-75.0M$-87.0M$-109.0M$-111.0M$-106.0M$-120.0M$-126.0M$-109.0M$-151.0M$-153.0M
Tax$-780,000$210,000$-310,000$-90,000$-70,000$-140,000$-550,000$-760,000$-470,000$-1.4M$1.9M$0
Net Profit$-59.0M$-51.0M$-75.0M$-87.0M$-109.0M$-111.0M$-106.0M$-121.0M$-127.0M$-111.0M$-148.0M$-153.0M
EPS$-0.45$-0.36$-0.52$-0.60$-0.74$-0.76$-0.64$-0.71$-0.73$-0.61$-0.73$-0.75

Over the 9 years reported for Immunovant, Inc., cash stood at $902.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 9.13 times.

Balance Sheet — 9 Years (USD millions)

Metric201820192020202120222023202420252026
Total Assets$0$0$109.0M$412.0M$516.0M$406.0M$667.0M$776.0M$958.0M
Current Assets$0$0$109.0M$409.0M$513.0M$404.0M$666.0M$768.0M$949.0M
Cash$0$0$101.0M$400.0M$494.0M$377.0M$635.0M$714.0M$902.0M
Inventory$0$0$0$0$0$0$0$0$0
Receivables$0$0$3.0M$1.0M$13.0M$1.0M$6.0M$3.0M$4.0M
Fixed Assets$0$0$0$3.0M$3.0M$2.0M$1.0M$1.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0
Total Liabilities$2.0M$0$15.0M$21.0M$46.0M$43.0M$49.0M$69.0M$105.0M
Current Liabilities$2.0M$0$15.0M$19.0M$45.0M$43.0M$49.0M$69.0M$104.0M
Borrowings$0$0$3.0M$3.0M$2.0M$1.0M$0$0$0
Other Liabilities$2.0M$0$12.0M$18.0M$43.0M$42.0M$49.0M$69.0M$105.0M
Equity$0$0$0$0$0$0$0$0$0
Reserves$-1.0M$0$94.0M$391.0M$470.0M$362.0M$618.0M$707.0M$853.0M

For Immunovant, Inc., operating cash flow was positive in 0 of 9 reported years; free cash flow in the latest year was negative at $407.0M; free cash flow was positive in 0 of 9 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 9 Years (USD millions)

Metric201820192020202120222023202420252026
Operating Cash Flow$-128.0M$-29.0M$-53.0M$-83.0M$-106.0M$-188.0M$-214.0M$-376.0M$-407.0M
Investing Cash Flow$0$0$0$0$-1.0M$0$-1.0M$-2.0M$0
Financing Cash Flow$128.0M$36.0M$109.0M$0$200.0M$0$0$4.0M$-1.0M
Net Cash Flow$0$7.0M$94.0M$300.0M$94.0M$-117.0M$259.0M$79.0M$188.0M
Free Cash Flow$-128.0M$-29.0M$-53.0M$-84.0M$-106.0M$-188.0M$-215.0M$-377.0M$-407.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-18.51
EV / EBITDA-11.47
FCF Yield-5.94%
Quick Ratio7.27
Interest Coverage—
Return 1Y130.81%
Return 3Y68.66%
Return 5Y297.57%

Immunovant, Inc. (IMVT) financials — frequently asked questions

What is Immunovant, Inc.'s annual revenue?

Immunovant, Inc. (IMVT) reported annual revenue of $0 in its most recent fiscal year.

What is Immunovant, Inc.'s net profit?

Immunovant, Inc. (IMVT) reported a net loss of $506.0M in its most recent fiscal year.

What is IMVT EV/EBITDA?

Immunovant, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -11.47. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
IMVT Overview IMVT Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.